What are analysts predicting for TSHA's Q1 2025 EPS?

Taysha Gene Therapies Inc. (TSHA) is not currently forming a consensus EPS prediction for Q1 2025. Here's an analysis based on available data:

1. Current Financial Performance Context:
   • TSHA reported a quarterly adjusted loss of $0.07 per share for the quarter ended December 31, 2024.
   • The mean expectation of eleven analysts for the quarter was for a loss of $0.08 per share.
   • Revenue fell 43.9% to $2.02 million from a year ago; analysts had expected $2.31 million.
2. Analyst Expectations and Trends:
   • The current average analyst rating on the shares is "buy," with a breakdown of 11 "strong buy" or "buy," no "hold," and no "sell" or "strong sell".
   • Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $7.00.
3. Historical Performance and Predictions:
   • TSHA has beaten its EPS estimate 75% of the time over the past 12 months.
   • The company has underperformed the market so far this year but has a history of surpassing consensus EPS estimates three times over the last four quarters.
4. Future Expectations and Considerations:
   • The mean earnings estimate of analysts was unchanged in the last three months.
   • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
5. Market Position and Outlook:
   • Despite the challenges, Taysha Gene Therapies Inc remains optimistic about its future, with Nvidia’s CEO stating that the industry is poised for growth, potentially becoming a multitrillion-dollar industry.

In conclusion, while specific EPS predictions for Q1 2025 are not available, historical performance and analyst sentiment suggest that TSHA is expected to continue facing challenges in the near term. However, the company's potential to outperform in the future, driven by industry growth and past performance beats, offers a cautiously optimistic outlook for long-term investors.